ESMO18: Roche details OS, PFS benefit for Tecentriq combination therapy in Phase III non-squamous NSCLC study

Roche on Monday presented detailed results from the Phase III IMpower130 study, showing that Tecentriq (atezolizumab) plus chemotherapy significantly improved survival versus chemotherapy alone as a first-line treatment for people with previously untreated metastatic non-squamous non-small-cell lung cancer (NSCLC). Data revealed that median overall survival (OS) in the two groups was 18.6 months and 13.9 months, respectively.

In June, the company announced that the trial met both of its primary endpoints, significantly improving both OS and progression-free survival (PFS). Findings detailed Monday at the European Society for Medical Oncology (ESMO) congress showed that patients who received Tecentriq plus chemotherapy had median PFS of 7 months, compared to 5.5 months for chemotherapy alone.

In the study, 723 chemotherapy-naïve patients with stage IV non-squamous NSCLC were randomly assigned to treatment with Tecentriq plus carboplatin and Celgene's Abraxane (nab-paclitaxel), or carboplatin and Abraxane alone. The co-primary endpoints of OS and PFS were assessed in patients without an EGFR or ALK mutation.

Roche noted that Grade 3/4 treatment-related adverse events (AEs) were reported in 73.2 percent of people receiving Tecentriq plus chemotherapy, compared to 60.3 percent of people receiving chemotherapy alone. The most common Grade 3/4 AEs in the Tecentriq plus chemotherapy group were neutropenia in 32.1 percent of people, anaemia in 29.2 percent and a decreased neutrophil count in 12.1 of patients.

"It's really another data point, another demonstration of the efficacy of cancer immunotherapy with Tecentriq in this disease," remarked Sandra Horning, Roche's chief medical officer, adding "we will work with global health authorities to bring this regimen to people living with this disease as soon as possible."

Tecentriq, which inhibits PD-L1, is already approved in the EU, the US and more than 70 countries for people with previously treated metastatic NSCLC and for certain types of untreated or previously treated metastatic urothelial carcinoma. The drug generated sales of 204 million Swiss francs ($205 million), in the third quarter, up 71 percent year-over-year.

To read more Top Story articles, click here.